Primary Immune Response Provides Protective Efficacy against SARS-CoV-2 Reinfection

Posted: 2021-09-11 19:00:00
While there is absolutely no evidence to ensure recovered patients are either likely or unlikely to get reinfected. But studies in non-human primates indicate that reinfection of recovered patients is highly unlikely. It is also clear that primary immune responses or induced immunity to severe acute respiratory syndrome coronavirus 2 remain in circulation for several months and at least temporarily confer immunity to protect from reinfection. In addition, negative virus culture analysis of re-positive suggests that positive reverse transcriptase-polymerase chain reactions in recovered patients are more likely to be false-positive, or detection of genetic remnants of virus discharged from lesions of lungs or better sampling at the time of repeat analysis. However, emerging severe acute respiratory syndrome coronavirus 2 variants are likely to be causing the infections observed in some of the recovered patients.

参考サイト PubMed: covid-19


7月 13, 2021 バイオアソシエイツ


以下、サンフランシスコ州立大学(SFSU)生物学部教授のマイケル・A・ゴールドマン博士(Michael A. Goldman)による記事より:今日、コンピューターモデルを使って構造や回復力のシミュレーションを行わずに、橋を架けて、その上を車でゆっくり走るエンジニアはいないだろう。それなのに、なぜ製薬会社は洗練されたシミュレーションを行わずに、動物や人間で薬を試す必要があるのだろうか? 2021年(6月14日~18日)に開催されたPrecision Medicine World…